Eye disease experts review treatments at EMA workshop

Article

The European Medicines Agency (EMA) hosted its first workshop for over 200 eye disease experts from all over the globe.

The European Medicines Agency (EMA) hosted its first workshop for over 200 eye disease experts from all over the globe.

The two-day workshop enabled the experts to review regulatory and scientific challenges encountered when developing eye disorder medicines.

Participants included European regulators, doctors and patient representatives from Australia, Japan, Europe and the USA. They discussed visual function measurement methods in clinical trials, stem cell development and retinal disease gene therapy. Other topics covered included macular disease treatments, inflammation treatments, corneal surface repair with stem cells and dry eye treatment methods.

Treatment developments for childhood eye disorders including retinal diseases in premature babies, childhood glaucoma, postoperative pain relief and childhood glaucoma were all discussed at the workshop.

Spiros Vamvakas, head of Scientific Advice at the EMA, said; "The workshop was successful in developing interactions between European regulators, doctors and patient representatives. We will now move forward with regulatory guidance in areas such as dry eyes and macular oedema, which will require further stakeholder input. Further discussion and research is needed before we can provide guidance in other areas such as trial designs and endpoints in inflammation of the eye, and advanced therapies in corneal and retinal disease."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.